Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by Arrakis37on Jul 29, 2021 10:29pm
67 Views
Post# 33630481

RE:you lose again francois, and me i post once:)

RE:you lose again francois, and me i post once:)

...as you see, Mr. Denial strike again...

Maybe in English for everyone...

https://electrodealpro.com/investors-the-richest-family-in-the-country-sued-for-700m/

LOL

The fun is about to begin


realstocky wrote: no lawsuit, this loser is only pushing

back Tom's posts. 

AMF Concludes its Review of the Refinancing Transactions Completed by Liminal BioSciences in April 2019

PRNewswire 28-Nov-2019 4:40 PM

LAVAL, QCROCKVILLE, MD and CAMBRIDGE, United KingdomNov. 28, 2019 /CNW Telbec/ - Liminal BioSciences Inc. (NASDAQ:LMNL) (TSX:LMNL) ( "Liminal BioSciences" or the "Company" ), a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat unmet needs in patients with liver, respiratory and kidney disease, acknowledges the press release issued today by the Autorit des Marchs Financiers ("AMF") in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019. The AMF is the regulatory and oversight body for Qubec's financial sector.

"We are pleased that the AMF has completed its review and concluded that it did not identify any violation or breach of securities regulation in the context of our refinancing transactions", stated Kenneth Galbraith, the Chief Executive Officer of Liminal BioSciences. "We have been cooperative and transparent with AMF throughout the review and look forward to focusing our efforts on developing and commercializing new medicines that may address serious unmet healthcare needs of patients around the world."

In April 2019, the Company completed a series of refinancing transactions, which were subject to the prior review and approval of the Toronto Stock Exchange. On November 18, 2019, the common shares of Liminal BioSciences commenced trading on the NASDAQ Global Market.



<< Previous
Bullboard Posts
Next >>